Pfizer mRNA Flu Vaccine
A Phase III, multicenter, clinical trial to evaluate the efficacy, safety, tolerability, and immunogenicity of the Pfizer quadrivalent modified RNA (modRNA) influenza vaccine candidate
AZD7442
admin48212023-03-31T17:31:31-04:00A Phase II Randomized, Open-label, Multicenter, Dose-ranging Study in adults and pediatric individuals 12 years of age and older to assess the safety, immunogenicity, pharmacokinetics, and pharmacodynamics of AZD7442, a combination of two Monoclonal Antibodies (Tixagevimab and Cilgavimab), for pre-exposure prophylaxis (prevention) of COVID-19
RSV-MVA-004
admin48212023-03-31T17:32:18-04:00A Randomized, Double-blind, Phase III trial to assess clinical efficacy, safety and reactogenicity of the recombinant MVA-BN® RSV vaccine in adults 60-years of age and older
#2019-01 C4591031
admin48212023-03-31T17:32:56-04:00A Phase 3 Master Protocol to evaluate additional dose(s) of BNt162b2 in healthy 12 to 30 year old individuals previously vaccinated with BNt162b2
IIT-2017-10117
admin48212023-05-02T13:41:31-04:00A pilot study for Allergan's intravenous antibiotic, Dalvance® (dalbavancin), administered every 14 days for the treatment of Septic Arthritis (2 infusions) and / or Osteomyelitis (3 infusions)